Early maternal plasma protein signatures identify preeclampsia risk in twin pregnancies
This study identifies a novel panel of early maternal plasma protein biomarkers, including annexin A2, annexin A3, chitotriosidase-1, and ferritin light chain, that significantly outperform conventional markers in predicting preeclampsia risk in twin pregnancies with a combined model achieving an AUC of 0.97.
Original paper dedicated to the public domain under CC0 1.0 (https://creativecommons.org/publicdomain/zero/1.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
Preeclampsia is a serious pregnancy complication where a woman's blood pressure rises dangerously high, often accompanied by damage to her kidneys and liver. It is a leading cause of illness and death for both mothers and babies. The condition is particularly dangerous for women carrying twins, who face a risk two to three times higher than women carrying a single baby. Currently, doctors rely on tools and blood tests developed for single-baby pregnancies to screen for this risk. However, these tools often fail to spot the danger early enough in twin pregnancies, leaving many women without the early warning they need to prevent the disease from taking hold. The core challenge is that twin pregnancies are biologically distinct; they involve a larger placenta and a much heavier workload for the mother's heart and blood vessels, meaning the warning signs might look different than they do in a singleton pregnancy.
A team of researchers at Peking University Third Hospital set out to find these missing warning signs by looking directly at the proteins floating in the blood of women carrying twins. They gathered blood samples from 84 women with twin pregnancies at three different stages: the first, second, and third trimesters. Half of these women eventually developed preeclampsia, while the other half remained healthy. Using a highly sensitive technique called mass spectrometry, which acts like a molecular scale to weigh and identify thousands of proteins at once, the scientists mapped out how the protein landscape changed over time. They were looking for a specific pattern of proteins that appeared in the blood of women who would later get sick, long before their blood pressure actually rose.
The researchers discovered that the standard blood markers used for single-baby pregnancies did not work for twins. Common indicators like sFlt-1 and PAPP-A showed no significant difference between the healthy twin pregnancies and those that developed preeclampsia. Instead, the team found a completely different set of proteins that told a different story. In the very first trimester, women who would later develop preeclampsia already showed a distinct signature: their blood contained higher levels of three specific proteins—annexin A3, chitotriosinase-1, and ferritin light chain—while a fourth protein, annexin A2, was lower than normal. These changes happened months before the disease became clinically apparent.
To confirm these findings, the researchers tested the blood samples again using a different method called ELISA, which is a standard lab test for measuring protein levels. The results held up. They then built a computer model to see how well these four proteins could predict the disease. When the model looked only at the protein levels, it was able to distinguish between healthy and at-risk pregnancies with high accuracy. When the researchers added basic information about the mothers, such as their age, weight before pregnancy, and blood pressure, the model became even more precise, correctly identifying the risk in nearly every case within their study group.
The team did not stop at finding the markers; they wanted to understand what these proteins were actually doing. They focused on annexin A2, the protein that was lower in the at-risk group. In the lab, they reduced the amount of this protein in human placental cells and watched what happened. The cells lost their ability to move and invade, which are critical steps for the placenta to attach properly to the uterus and build a strong blood supply. This suggests that when annexin A2 is low, the placenta may not develop correctly, setting the stage for the high blood pressure and other problems that define preeclampsia. They also found that the specific biological pathways involved in twin preeclampsia differed from those in single-baby pregnancies, particularly regarding how the body handles iron and inflammation.
While the results are promising, the researchers are careful to note that this is an early discovery. The study was conducted at a single hospital with a relatively small number of participants, and the findings have not yet been tested in a larger, diverse group of people. The authors emphasize that these results are a starting point for developing a new, twin-specific screening tool, but they are not yet ready for use in clinics. The work proves that twin pregnancies are not just a bigger version of singleton pregnancies; they have their own unique biological rhythm and warning signs. By listening to these specific signals in the mother's blood, doctors may one day be able to identify the risk of preeclampsia in twin pregnancies much earlier, allowing for better care and safer outcomes for mothers and their babies.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.